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ARTICLE
A requirement for STAG2 in replication fork
progression creates a targetable synthetic
lethality in cohesin-mutant cancers
Gourish Mondal1, Meredith Stevers1, Benjamin Goode 1, Alan Ashworth2,3 & David A. Solomon 1,2
Cohesin is a multiprotein ring that is responsible for cohesion of sister chromatids and
formation of DNA loops to regulate gene expression. Genomic analyses have identified that
the cohesin subunit STAG2 is frequently inactivated by mutations in cancer. However, the
reason STAG2 mutations are selected during tumorigenesis and strategies for therapeutically
targeting mutant cancer cells are largely unknown. Here we show that STAG2 is essential for
DNA replication fork progression, whereby STAG2 inactivation in non-transformed cells leads
to replication fork stalling and collapse with disruption of interaction between the cohesin ring
and the replication machinery as well as failure to establish SMC3 acetylation. As a con-
sequence, STAG2 mutation confers synthetic lethality with DNA double-strand break repair
genes and increased sensitivity to select cytotoxic chemotherapeutic agents and PARP or
ATR inhibitors. These studies identify a critical role for STAG2 in replication fork procession
and elucidate a potential therapeutic strategy for cohesin-mutant cancers.
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Cohesin is a multi-protein complex composed of four coresubunits (SMC1A, SMC3, RAD21, and either STAG1 orSTAG2) that is responsible for the cohesion of sister
chromatids. Cohesin genes were originally identified in yeast as
mutants that displayed premature separation of sister chromatids,
and were later identified as being highly conserved from yeast to
mammals1. The cohesin subunits form a ring-shaped structure
that encircles chromatin, which is loaded onto chromatin in early
G1 phase of the cell cycle immediately following cytokinesis and
concatenates sister chromatids during DNA replication in S
phase. Cohesin remains chromatin bound specifically at cen-
tromeres in prophase of mitosis while the majority of cohesin
along chromatid arms is released, and then the remainder of
chromatin-bound cohesin is cleaved at the metaphase to ana-
phase transition to enable segregation of the sister chromatids
into two daughter cells. Recent studies have found that cohesin
containing the more abundant STAG2 subunit is essential for
chromatid cohesion at centromeres and along chromosome arms,
while cohesin containing the less abundant STAG1 subunit is
essential for chromatid cohesion specifically at telomeres2,3.
In addition to its canonical role in sister chromatid cohesion,
studies have indicated that cohesin is essential for a multitude of
other cellular functions. Notably, cohesin was recently shown to
be required for the formation of chromatin loops, such as those
that bring together distant superenhancers with immediate
upstream promoter sequences to regulate gene expression4–6.
While cohesin forms a ring-like structure that encircles chro-
matin, no DNA binding motifs with nucleotide sequence speci-
ficity have been identified within the core cohesin subunits.
However, emerging studies have shown that cohesin is enriched
at specific chromatin loci including active transcriptional sites
and pericentric heterochromatin, suggesting cohesin localization
is directed by specific DNA-binding regulatory proteins. The
CCCTC-binding factor (CTCF) has been identified as a direct
binding partner of STAG2 that is dispensable for cohesin loading
onto chromatin but is required for cohesin enrichment at specific
enhancer regulatory loci throughout the genome7,8.
While cohesin is known to be loaded onto chromatin imme-
diately following cytokinesis at the completion of mitosis, it is
during DNA replication in S-phase when this pool of cohesin
concatenates sister chromatids to establish cohesion9–11. Recent
studies have demonstrated that the MCM replicative helicase
complex is critical for this cohesion establishment during S-
phase12,13. However, the extent to which cohesin is essential for
DNA replication is largely unknown, as is the effect that cohesin
gene mutations in human cancers might have on stability and
procession of replication forks. Notably, recent studies in yeast
have hypothesized a role for cohesin in replication fork dynam-
ics14–16.
Germline mutations in the cohesin subunits or in genes
responsible for cohesin loading (e.g., NIPBL) or regulation (e.g.,
HDAC8 and ESCO2) cause a spectrum of severe developmental
syndromes characterized by facial dysmorphism, growth retar-
dation, mental retardation, and limb anomalies. Depending on
the gene affected, these have been termed Cornelia de Lange
syndrome, Roberts syndrome, and other eponyms, which are now
all considered to be “cohesinopathies”17–20. Analysis of cells from
affected patients found precocious separation of sister chromatids
before anaphase in mitosis, which was hypothesized to be a
causative mechanism in these syndromes21. However, subsequent
studies have not observed similar defects in sister chromatid
cohesion, calling into question the functional consequence of
cohesin mutations in the germline of affected patients. Genome-
wide transcriptional profiling in cells derived from Cornelia de
Lange syndrome patients with NIPBL or SMC1A mutations ver-
sus normal subjects has revealed a conserved pattern of
transcriptional dysregulation22,23. As a result, these cohesino-
pathy syndromes are now widely regarded to result from
deregulated gene expression during development.
Recent genomic analyses of human cancer have identified that
the cohesin genes, and STAG2 in particular, are frequent targets
of mutational inactivation in a select subset of tumor types that
include glioblastoma, urothelial carcinoma, Ewing sarcoma, and
myeloid leukemia24–29. STAG2 has been identified as one of only
12 genes that are significantly mutated in four or more human
cancer types by The Cancer Genome Atlas30, in which STAG2
mutation defines molecular subgroups of these tumor types with
distinct clinical outcomes24,25,27,28. Initial studies in glioblastoma
cell lines suggested a role for STAG2 mutations as a cause of
chromosomal instability and aneuploidy during tumorigenesis26.
However, the majority of urothelial carcinomas, Ewing sarcomas,
and myeloid leukemias harboring STAG2 mutations are actually
diploid or near-diploid tumors, suggesting that cohesin mutations
in cancer likely promote tumorigenesis by mechanisms unrelated
to chromosome segregation25,27–29. The exact reasons why
inactivating cohesin mutations are selected for during cancer
development and progression are still uncertain. In one recent
study, STAG2 mutations were found to be acquired after therapy
with RAF inhibitors in BRAF-mutant melanomas as a mechanism
of therapeutic resistance31. However, the majority of STAG2
mutations in glioblastoma, urothelial carcinoma, and Ewing
sarcoma are clonal events that likely arise early during tumor
development. The therapeutic consequences of cohesin mutations
in these cancers are largely unknown at present, as are meth-
odologies for treating cohesin-mutant cancers using a precision
medicine approach.
Here we investigated the function of the cohesin subunit
STAG2 in primary non-transformed human cells to discern the
basic cellular processes regulated by this gene that serves as a
scaffold between the cohesin ring and the nuclear proteome. We
find an essential role for STAG2 in the procession of DNA
replication forks. Deficiency of STAG2 results in disruption of the
interaction of cohesin with the replication machinery, leading to
stalling and collapse of replication forks, as well as failure to
establish SMC3 acetylation. As a consequence, STAG2 deficiency
confers synthetic lethality with specific DNA repair genes and
increased sensitivity to select chemotherapeutic agents. Our data
provide the preclinical rationale for targeted therapy-based clin-
ical trials for cohesin mutant cancers.
Results
Inactivation of STAG2 in primary human cells results in intra-
S-phase cell cycle arrest and senescence. To study the function of
STAG2 in non-transformed human cells, we used the CRISPR/
Cas9 system to inactivate the STAG2 gene in hTERT-
immortalized retinal pigmented epithelial (RPE) cells. RPE cells
were transfected with an expression vector that encodes Cas9, a
guide RNA specific to STAG2, and green fluorescent protein
(GFP). Following sorting for GFP-positive cells at 48 h after
transfection, evidence of Cas9 cleavage was detected by Sanger
sequencing (Fig. 1a). All GFP-positive cells failed to proliferate
after sorting, and instead displayed morphologic changes asso-
ciated with cellular senescence (Fig. 1b). This suggested that
STAG2 might be a required gene in primary, non-transformed
human cells.
To mechanistically study the requirement for STAG2 in non-
transformed human cells, we performed lentiviral transduction
with two independent shRNA sequences against the STAG2
mRNA on three cell lines: RPE, BJ (an hTERT-immortalized
human fibroblast cell line), and SVG p12 (an immortalized
human fetal astrocyte cell line). Both shRNA sequences resulted
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in a sustained depletion of >99% of STAG2 protein (Fig. 1c). Both
shRNAs resulted in an accumulation of cells stalled within S-
phase of the cell cycle apparent in all three cell lines as early as 48
h after infection, with failure to enter G2/M over an extended
time interval (Fig. 1d, Supplementary Fig. 1a, 1b). Assessment of
the three cell lines after STAG2 depletion revealed failure to
proliferate and morphologic features of cellular senescence
including beta-galactosidase activity (Fig. 1e, f, Supplementary
Fig. 1c–1e). To further confirm this finding, lentiviral transduc-
tion of three additional independent shRNA sequences against
the STAG2 mRNA using the pGIPZ vector system was performed
on RPE cells, which resulted in an identical phenotype of intra-S-
phase arrest, failure to proliferate, and morphologic features of
senescence (Supplementary Fig. 1f–1h). Together, these data
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Fig. 1 Inactivation of the cohesin regulatory subunit STAG2 in primary human cells results in intra-S-phase cell cycle arrest and senescence, whereas the
core cohesin subunits SMC1A, SMC3, and RAD21 are essential for cell viability. a Sequence alignment of STAG2 genomic DNA isolated from RPE cells (top)
with wildtype STAG2 and after Cas9 cleavage with gRNA targeting the STAG2 locus (bottom). b Phase contrast image of RPE cells following ectopic
expression of Cas9 and STAG2 gRNA, which uniformly showed morphologic features of senescence and failure to proliferate. c Immunoblot of total lysate
from RPE cells following shRNA depletion of STAG2 expression using two independent shRNA sequences (sh1221 and sh3782). d Flow cytometry plots of
RPE cells following lentiviral transduction with empty pLKO.1 or STAG2 shRNA demonstrating an abnormal accumulation of cells within S-phase after
STAG2 depletion. e Phase contrast image of RPE cells following lentiviral transduction with empty pLKO.1 or STAG2 shRNA demonstrating morphologic
features of senescence and failure to proliferate. f RPE cells at 14 days following lentiviral transduction with STAG2 shRNA show β-galactosidase activity
characteristic of senescence. g Phase contrast image of RPE cells following lentiviral transduction with shRNAs against cohesin components (left), and
summary of observed cellular phenotype (right). Source data are provided as a Source Data file
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indicate that acute STAG2 inactivation in non-transformed
human cells leads to an intra-S-phase cell cycle arrest and
senescence.
Core cohesin ring subunits are essential for cell viability. To
assess the cellular phenotypes caused by inactivation of the other
cohesin components, we performed lentiviral transduction with
two independent shRNAs against each of the core cohesin genes.
Both shRNA sequences resulted in >99% depletion of the target
proteins (Supplementary Fig. 1i). Depletion of the cohesin ring
subunits SMC1A, SMC3, and RAD21 in primary human cells
resulted in death of the vast majority of cells, with the few sur-
viving RAD21 shRNA transduced cells showing morphologic
features of senescence (Fig. 1g, Supplementary Fig. 1j). In con-
trast, no decreased proliferation or death was observed following
STAG1 depletion. These results demonstrate that STAG2 has
unique, non-redundant cellular functions compared to STAG1,
whereas the core cohesin ring subunits are essential for viability
in primary non-transformed human cells.
Inactivation of STAG2 in primary human cells causes replica-
tion fork stalling. In order to assess the mechanism of the intra-
S-phase cell cycle arrest induced by STAG2 depletion, we estab-
lished a single fiber DNA replication assay in RPE cells that
enables assessment of the progression of individual replication
forks (Supplementary Fig. 2a, 2b). Using this methodology, we
studied replication fork progression upon STAG2 depletion
(Fig. 2a, b). We observed a significant increase in the number of
stalled replication forks in cells transduced with two independent
STAG2 shRNAs but not empty vector (Fig. 2c, Supplementary
Fig. 2c, 2d). We next assessed localization of the p34 isoform of
replication protein A (RPAp34), a single-stranded DNA binding
protein that does not visibly accumulate at replication sites under
normal S-phase conditions, but focally accumulates at stalled
replication forks induced by the DNA polymerase inhibitor
aphidicolin or the topoisomerase-II inhibitor etoposide (Supple-
mentary Fig. 2e)32. Upon STAG2 depletion, RPAp34 accumu-
lated at stalled replication foci, similar to that observed upon
replication block with aphidicolin (Fig. 2d, e, Supplementary
Fig. 2f).
Inactivation of STAG2 in primary human cells causes disrup-
tion of cohesin interaction with the replication machinery. To
investigate the function of the cohesin ring at the replication fork,
we next assessed for protein-protein interactions between the
cohesin subunit SMC3 and the origin recognition complex
(ORC1, ORC3), replication licensing factors (CDC45, CDC6,
CDT1, and Geminin), the MCM helicase complex (MCM3,
MCM5), and the DNA replication machinery (AND1/Ctf4, pro-
liferating cell nuclear antigen [PCNA], DNA polymerase epsilon
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Fig. 2 The intra-S-phase cell cycle arrest caused by inactivation of STAG2 in primary human cells is due to replication fork stalling. a Schematic diagram of
DNA combing assay to measure DNA replication progression in cultured human cells. Arrows indicate example of DNA fibers with replication stalling or
termination. b Microscopic images of representative single DNA fibers showing normal replication fork progression (top) and replication fork stalling
during IdU pulse (middle) and CldU pulse (bottom). c Quantitation of normal and abnormal replication forks scored from DNA combing assay of RPE cells
following lentiviral transduction with empty pLKO.1 or two independent STAG2 shRNAs. More than 200 individual replication forks were evaluated from
two independent experiments for each condition. *p < 0.0001, Mann–Whitney unpaired nonparametric t-test analysis. d Representative images of RPE cells
showing accumulation of GFP-tagged RPAp34 at stalled replication forks following lentiviral transduction with STAG2 shRNA but not empty pLKO.1.
e Quantitation of RPE cells containing discrete foci of GFP-RPAp34 at stalled replication forks following lentiviral transduction with empty pLKO.1 vector,
two independent STAG2 shRNAs, or following treatment with aphidicolin for 16 h. More than 600 cells were evaluated from three independent experiments
for each condition, and error bars show standard error of the mean. Source data are provided as a Source Data file
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[PolE], and DNA polymerase delta [PolD]). We identified across
a panel of multiple human cell lines that the cohesin ring phy-
sically associates with both the pre-replication complex and the
replication machinery at the replication fork, but failed to identify
an interaction with the origin recognition complex (Fig. 3a,
Supplementary Fig. 3a). Next, we performed immunoprecipita-
tion using antibodies against cohesin subunits and cohesin
regulatory factors to determine the specificity of interaction with
the replication helicase MCM3. We found that MCM3 specifically
associates with STAG2, SMC3, SMC1A, and PDS5A, but not the
cohesin regulatory factors NIPBL and Securin (Fig. 3b, c, Sup-
plementary Fig. 3b). In order to assess the cell cycle specificity of
the interaction between cohesin and replication factors, immu-
noprecipitation was performed using SMC3 antibodies on RPE
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cells either asynchronously proliferating (+DMSO vehicle),
arrested in G1 phase using the cyclin-dependent kinases 4/6
(CDK4/6) inhibitor palbociclib, arrested in S phase using the
DNA polymerase inhibitor aphidicolin, or arrested in mitosis
using the microtubule polymerization inhibitor colcemid. The
interaction between cohesin and the replication factors was
enriched during S-phase arrest, was absent during mitotic arrest,
and was diminished during G1 arrest (Fig. 3d). In contrast, SMC3
interaction with Securin, a mitotic regulator of cohesin, was
enriched during mitotic arrest and was diminished during G1 and
S phase arrest. In order to determine whether the interaction of
cohesin with replication factors is indirectly mediated by chro-
matin association, immunoprecipitation with SMC3 antibodies
was performed in the presence of either DNase or MNase treat-
ment (Fig. 3e). These nuclease treatments did not prevent the
interaction of SMC3 with either pre-replication factors or the
replication machinery (Fig. 3e).
We next studied how STAG2 inactivation perturbs the
association of cohesin with the replication machinery. shRNA
depletion of STAG2 caused a complete disruption of cohesin
interaction with PCNA, the sliding clamp essential for normal
processivity of DNA replication, and also reduced association
with DNA polymerases PolD and PolE (Fig. 3f, Supplementary
Fig. 3c). In contrast, STAG2 depletion resulted in increased
association of cohesin with the single-stranded DNA binding
protein RPAp34, and also enhanced binding with the MCM
helicase complex and multiple replication licensing factors
including Geminin, a negative regulator of DNA replication
known to be essential for preventing genome reduplication33,34.
These data indicate a critical role for the cohesin ring in
coordinating the stability and procession of DNA synthesis at the
replication fork.
Inactivation of STAG2 in primary human cells results in failure
to establish SMC3 acetylation. Sister chromatid cohesion is
established during S-phase by the cohesin complex, which is
known to be governed by acetylation of the cohesin subunit
SMC3 by the acetyltransferase enzyme ESCO235–39. Biallelic
germline mutations in the ESCO2 gene are the cause of Roberts
syndrome, a cohesinopathy characterized by tetraphocomelia
(symmetrical limb reduction), craniofacial anomalies, growth
retardation, mental retardation, and cardiac and renal abnorm-
alities (Online Mendelian Inheritance in Man #268300). We
therefore assessed whether the DNA replication fork stalling
induced by STAG2 deficiency may be due to impaired SMC3
acetylation. shRNA depletion of STAG2 in RPE cells abolished
SMC3 acetylation (Fig. 3g, h), indicating that STAG2 is required
for this critical post-translational modification of the cohesin ring
during DNA replication.
STAG2 absence leads to replication fork collapse, DNA double-
strand breaks, and DNA damage checkpoint activation. To
evaluate the consequence of replication fork stalling induced by
STAG2 inactivation, we investigated whether this may lead to
replication fork collapse and DNA double-strand breaks. We
observed accumulation of 53BP1 foci, a marker of DNA double-
strand breaks but not normal replication sites, in the three non-
transformed human cell lines upon shRNA depletion of STAG2
(Fig. 4a, b). In order to assess whether 53BP1 foci were resulting
from replication fork collapse, we performed shRNA depletion on
cells arrested in G1 phase of the cell cycle using the CDK4/6
inhibitor palbociclib (Supplementary Fig. 4a, 4b). No 53BP1 foci
were observed in cells arrested in G1 phase of the cell cycle;
however, upon release from palbociclib arrest, STAG2-depleted
cells developed 53BP1 foci within a few hours, indicating that
these most likely result from collapsed replication forks after
entry into S-phase (Fig. 4c, Supplementary Fig. 4c). Commen-
surate with induction of 53BP1 foci accumulation, STAG2
depletion in multiple non-transformed human cell lines resulted
in activation of DNA damage checkpoint signaling, as evidenced
by a robust increase in phosphorylated isoforms of ATM, ATR,
BRCA1, Chk2, and p53 proteins, as well as upregulation of the
cell cycle checkpoint inhibitor p21WAF1/CIP1 (Fig. 4d). Together,
these data indicate that acute inactivation of STAG2 in non-
transformed human cells leads to induction of DNA double-
strand breaks likely due to replication fork collapse that results in
activation of DNA damage checkpoint signaling.
The intra-S-phase cell cycle arrest but not the loss of SMC3
acetylation induced by STAG2 inactivation is p53 dependent.
While acute inactivation of STAG2 in non-transformed human
cells results in cell cycle arrest, STAG2 homozygous deletion or
inactivating truncating mutations are commonly selected for
during the development of glioblastoma, urothelial carcinoma,
Ewing sarcoma, acute myeloid leukemia, and other human cancer
types, whereby this genetic inactivation likely functions to pro-
mote some aspect of tumor survival or growth. Multiple studies
have noted a strong association of STAG2 inactivation and TP53
mutation in Ewing sarcoma, whereby the combination of these
two genetic alterations is significantly associated with poor prog-
nosis relative to STAG2 and TP53 wildtype tumors24,28. We thus
speculated that p53 function may be an important modulator of
the cellular senescence phenotype seen in non-transformed cells
versus the pro-tumorigenic phenotype seen in human cancers
with STAG2 inactivation. Therefore, we tested the effects of dual
depletion of STAG2 and TP53 in hTERT-immortalized RPE cells
(Fig. 5a). We observed a bypass of the intra-S-phase cell cycle
arrest and cellular senescence induced by STAG2 inactivation
alone (Fig. 5b, c, Supplementary Fig. 5). We therefore anticipated
being able to successfully knockout STAG2 in TP53-depleted
Fig. 3 Inactivation of STAG2 in primary human cells causes disruption of cohesin interaction with the replication machinery along with failure to establish
SMC3 acetylation. a Immunoprecipitation using antibodies against the cohesin subunit SMC3 pulls down multiple components of the pre-replication
complex and replication machinery, but not the origin recognition complex, across a spectrum of human cell lines. b Immunoprecipitation using STAG2
antibodies demonstrating interaction of the replication helicase MCM3 with STAG2. c Summary of immunoprecipitation results in HeLa and RPE cells
demonstrating a specific interaction of MCM3 with the cohesin subunits STAG2, SMC3, SMC1A, and PDS5A, but not the cohesin regulatory factors NIPBL
and Securin. d Immunoprecipitation using SMC3 antibodies of lysates collected from RPE cells following treatment with DMSO vehicle, the CDK4/6
inhibitor palbociclib, the DNA polymerase inhibitor aphidicolin, and the microtubule polymerization inhibitor colcemid. e Immunoprecipitation of lysates
from RPE cells using SMC3 antibodies in the presence of DNA nuclease treatment. f shRNA depletion of STAG2 disrupts cohesin interaction with the
replication factors PCNA, DNA polymerase epsilon, and DNA polymerase delta, while enhancing the interaction with the single-stranded DNA binding
protein RPA/p34, the MCM helicase complex, and replication licensing factors (CDC6, CDT1, and Geminin). g, h Assessment of SMC3 acetylation in RPE
cells after lentiviral transduction with empty pLKO.1 or two independent STAG2 shRNAs. Shown are immunoblots using antibodies against acetylated-
lysine following SMC3 immunoprecipitation (g), as well as immunoblots of total SMC3 and STAG2 proteins on whole cell lysates (h). Source data are
provided as a Source Data file
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primary human cells, as well as TP53-mutant human cancer cell
lines. Indeed, using the same CRISPR mediated gene targeting
approach as performed on parental RPE cells that failed to pro-
duce knockout clones (Fig. 1a, b), we were able to produce STAG2
knockout clones at high efficiency in p53-depleted RPE cells and
multiple Ewing sarcoma cell lines harboring inactivating TP53
mutations (Fig. 5d–g). These results demonstrate that the intra-S-
phase cell cycle arrest induced by STAG2 inactivation is p53
dependent and help to explain the frequent co-occurrence of
STAG2 and TP53 mutation in Ewing sarcoma.
In order the explore the mechanism by which TP53
inactivation allows bypass of the intra-S-phase arrest in STAG2
mutant cells, we performed immunoprecipitation reactions using
SMC3 antibodies to study the binding of cohesin with the DNA
replication machinery in STAG2-depleted RPE cells with and
without simultaneous shRNA knockdown of p53. Simultaneous
knockdown of p53 expression restored the interaction of cohesin
with the replication factors PCNA, PolE, and PolD, as well as
prevented the enhanced binding of cohesin with MCM3, MCM5,
CDT1, and Geminin (Fig. 5h). However, simultaneous TP53
knockdown did not block the enhanced interaction of cohesin
with RPAp34 or CDC6. Thus, while p53 is a critical regulator of
replication fork procession in STAG2 mutant cells, there are
perturbations of the interaction between cohesin and replication
factors (e.g., RPAp34 and CDC6) that are independent of p53
control.
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Fig. 4 The replication fork stalling caused by STAG2 depletion leads to fork collapse, DNA double-strand breaks, and DNA damage checkpoint activation.
a Representative immunofluorescence images of RPE and SVG p12 cells following lentiviral transduction with empty pLKO.1 or two independent STAG2
shRNAs showing spontaneous accumulation of 53BP1 foci. b Quantitation of RPE, BJ, and SVG p12 cells with greater than ten 53BP1 foci following lentiviral
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each condition, and error bars show standard error of the mean. c Representative immunofluorescence images demonstrating that 53BP1 foci formation
after STAG2 depletion is dependent on cell cycle proliferation. Cells were arrested in G1 phase of the cell cycle using palbociclib, followed by lentiviral
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lysate from RPE and SVG p12 cells for DNA damage response proteins following lentiviral transduction with empty pLKO.1 or two independent STAG2
shRNAs. Source data are provided as a Source Data file
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As we observed disruption of SMC3 acetylation following
STAG2 depletion in TP53-wildtype cells that is known to be
required for establishment of sister chromatid cohesion during
DNA replication, we investigated the status of SMC3 acetylation
in RPE cells after dual depletion of STAG2 and TP53, as well as in
paired isogenic STAG2 glioblastoma (H4) and Ewing sarcoma
(TC-106) cell lines. We have previously used homologous
recombination to correct the endogenous STAG2 mutant allele
in the H4 human glioblastoma cell line26. We observed that
concomitant depletion of TP53 was not sufficient to restore the
abrogation of SMC3 acetylation in RPE cells (Fig. 5i). Addition-
ally, we found that the levels of SMC3 acetylation were impaired
in cancer cells lines harboring STAG2 inactivation (H4 parental
and TC-106 STAG2 knockout cells) relative to their STAG2
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wildtype counterparts (H4 STAG2 knock-in and TC-106 parental
cells) (Fig. 5j). These results indicate that STAG2 is critical for
SMC3 acetylation independent of p53 function, and that cancer
cells with concomitant STAG2 and TP53 inactivation escape
cellular senescence despite abrogation of SMC3 acetylation.
STAG2 deficiency in human cancer cells creates a synthetic
lethality with STAG1, whereas the other core cohesin subunits
are required independent of STAG2 status. Two recent studies
have both demonstrated that STAG2 mutant cancer cells have a
critical dependence on STAG140,41. We observed no significant
growth inhibition or cell death upon lentiviral shRNA knock-
down of >99% of STAG1 protein in hTERT-immortalized pri-
mary human cells with wildtype STAG2, whereas shRNA
knockdown of >99% of SMC3, SMC1A, and RAD21 proteins
resulted in cell death (Fig. 1g, Supplementary Fig. 1i, 1j). In order
to investigate the genetic dependencies for these core cohesin
genes in cancer cells harboring inactivating STAG2 mutations,
lentiviral shRNA transduction using two independent shRNA
sequences for each cohesin subunit was performed in four pairs of
isogenic STAG2 human cell lines (H4 glioblastoma, 42MGBA
glioblastoma, TC-106 Ewing sarcoma, and RPE primary epithelial
cells with hTERT overexpression and TP53 depletion). In keeping
with the two recent studies, STAG1 depletion had no significant
growth inhibition on STAG2 proficient cells, whereas STAG1
depletion uniformly resulted in cell death across all four of the
STAG2 deficient cells (Fig. 6a, b, Supplementary Fig. 6). In
contrast, SMC3, SMC1A, and RAD21 were essential genes in all
four isogenic pairs, with cell death uniformly observed in both
STAG2 proficient and deficient cells (Fig. 6a).
STAG2 deficiency in human cancer cells creates a synthetic
lethality with DNA double-strand break repair factors. Given
the large burden of collapsed replication forks and DNA double-
strand breaks in STAG2 deficient cells, we hypothesized that
STAG2 mutational inactivation might create a synthetic lethality
with factors critical for DNA damage repair. We thus performed
an shRNA-based synthetic lethality screen in the four pairs of
isogenic STAG2 human cell lines, which included genes known to
be essential for homologous recombination (HR), non-
homologous end-joining (NHEJ), base excision repair (BER),
and nucleotide excision repair (NER). We first validated efficient
shRNA depletion of each of the ten DNA repair genes and
selected two independent hairpin sequences that produced >90%
knockdown for performing the screen (Supplementary Fig. 7a).
Across all four isogenic pairs, STAG2-deficiency correlated with a
significant decrease in survival following shRNA depletion of
genes responsible for DNA double-strand break repair via either
HR or NHEJ (e.g., ATR, BRCA1, RAD51, XRCC5, and PRKDC)
relative to their isogenic STAG2-proficient counterparts
(Fig. 7a–e, Supplementary Fig. 7b–7f). In contrast, no significant
difference in survival was observed in the four isogenic pairs
following shRNA depletion of genes responsible for BER and
NER (e.g., APEX1, POLB, ERCC1, and ERCC4). We observed a
variable difference in survival using shRNA against PARP1, which
encodes a poly-ADP-ribosyltransferase critical for DNA double-
strand break repair, that may be due to insufficient shRNA
depletion or possibly redundancy with additional PARP isoforms
encoded in the human genome. Together, these results highlight a
critical dependency for DNA double-strand break repair, but not
excision repair, in STAG2 mutant cells.
Given this finding, we speculated that STAG2 mutant cells may
show increased sensitivity to ionizing radiation via synergizing
with the replication fork disruption to cause a catastrophic
accumulation of DNA double-strand breaks. Four pairs of
isogenic STAG2 human cells were subjected to varying doses of
either gamma-irradiation or ultraviolet irradiation, and the effects
on cellular survival were assessed. Across all four isogenic pairs,
STAG2-deficiency correlated with a significant decrease in
survival following gamma-radiation compared to their isogenic
STAG2-proficient counterparts (Fig. 7f, Supplementary Fig. 7g).
In contrast, no significant difference in survival was observed in
the four isogenic pairs following ultraviolet irradiation (Fig. 7f,
Supplementary Fig. 7h). These results further highlight the
dependency for DNA double-strand break repair, but not
excision repair, in STAG2 mutant cells.
STAG2 deficient cancer cells harbor increased sensitivity to
cytotoxic chemotherapeutic agents and inhibitors of DNA
double-strand break repair. While STAG2 mutational activation
is known to be frequent in glioblastoma, Ewing sarcoma, and
urothelial carcinoma, the effect of STAG2 status on the response
to cytotoxic chemotherapy agents routinely used in the treatment
of these cancer types is largely unknown. We therefore investi-
gated the response of four isogenic STAG2 human cell pairs (two
glioblastoma, one Ewing sarcoma, and one hTERT-immortalized
epithelial cell line) to a panel of commonly used cytotoxic che-
motherapy agents and small molecule inhibitors with various
mechanisms of action. We observed that STAG2-deficiency
across all four isogenic pairs correlated with a significant
decrease in survival following treatment with DNA alkylating
agents, DNA crosslinking agents, topoisomerase inhibitors, PARP
inhibitors, and ATR inhibitors (Fig. 8a, b, Supplementary Fig. 8a–
8d). In contrast, no significant difference in survival was observed
Fig. 5 The intra-S-phase cell cycle arrest but not the loss of SMC3 acetylation induced by STAG2 inactivation is p53 dependent. a Immunoblot of total
lysate from RPE cells following lentiviral STAG2 shRNA depletion either alone or in combination with TP53 shRNA depletion. b Flow cytometry plot of RPE
cells following lentiviral transduction with STAG2 shRNA in combination with TP53 shRNA demonstrating bypass of the S-phase arrest induced by STAG2
depletion alone. c Phase contrast image of RPE cells following lentiviral transduction with STAG2 shRNA in combination with TP53 shRNA demonstrating
cellular proliferation and abrogation of the senescence induced by STAG2 depletion alone. d Sequence alignment of representative STAG2 knockout clones
that were readily obtained following ectopic expression of Cas9 and STAG2 gRNA in RPE cells subsequent to TP53 shRNA depletion. e Results of STAG2
knockout clone generation following ectopic expression of Cas9 and STAG2 gRNA in multiple human cell lines with wildtype TP53, TP53 shRNA depletion,
or mutant TP53 alleles. f Immunoblots of total lysate from several of the STAG2 knockout clones generated by Cas9 cleavage in RPE cells with TP53 shRNA
depletion. g Immunoblots of total lysate from the STAG2 knockout clone generated by Cas9 cleavage in TC-106 Ewing sarcoma cells harboring TP53 splice
site mutation. h TP53 inactivation via lentiviral shRNA depletion in STAG2-depleted RPE cells restores the interaction of cohesin with the replication factors
PCNA, PolE, and PolD, as well as blocking the enhanced binding of cohesin with MCM3, MCM5, CDT1, and Geminin. However, TP53 inactivation does not
block the enhanced interaction of cohesin with RPAp34 or CDC6. i Combined STAG2 and TP53 shRNA depletion enables bypass of S-phase cell cycle arrest
independent of SMC3 acetylation. Shown are immunoblots using antibodies against acetylated-lysine following SMC3 immunoprecipitation, as well as
immunoblots of total SMC3 and STAG2 on whole cell lysates of RPE cells after lentiviral shRNA transduction. j Impaired SMC3 acetylation is present in H4
glioblastoma cells with STAG2 truncating frameshift mutation and TC-106 Ewing sarcoma cells after STAG2 knockout by targeted Cas9 cleavage. Source
data are provided as a Source Data file
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in the four isogenic pairs following treatment with inhibitors of
tyrosine kinases, 26S proteasome, RNA polymerase, mTOR,
histone deacetylase (HDAC), and microtubule polymerization.
To further confirm the differential sensitivity of STAG2-
proficient versus deficient cancer cells to DNA damaging che-
motherapeutic agents, we performed clonogenic survival assays
with the DNA alkylating agent cyclophosphamide. Cyclopho-
sphamide treatment significantly reduced colony formation in
STAG2 mutant cells relative to their STAG2 wildtype counter-
parts in all four isogenic pairs (Supplementary Fig. 8e, 8f).
Discussion
Subunits of the cohesin complex have emerged as frequent targets
of somatic mutation in human tumors over the past decade of
cancer genomics research. However, methods to therapeutically
target cohesin-mutant cancers are currently unknown. Herein we
have identified an essential role for the STAG2 gene in stability of
the replication fork that creates a targetable synthetic lethality in
STAG2 mutant cancers.
In order to study the fundamental cellular processes controlled
by STAG2, we used multiple genetic mechanisms to inactivate
STAG2 function in primary non-transformed human cells. Both
CRISPR knockout and shRNA depletion revealed that STAG2 is
required for cellular proliferation but not cell viability across a
range of normal human cell types including epithelial cells,
fibroblasts, and glial cells. In contrast, inactivation of the cohesin
ring subunits SMC1A, SMC3, and RAD21 is not compatible with
viability in both primary non-transformed human cells and
human cancer cell lines. The reason why cohesin mutations in
human cancers most commonly affect STAG2 and less commonly
the other cohesin subunits has been unknown. We and others
have speculated that this may be in part because the STAG2 gene
is on the X chromosome and therefore requires only a single
genetic event in order to achieve loss of function, whereas the
other cohesin subunits located on the autosomes require two
genetic events. However, our findings indicate that truncating
mutations in cohesin ring subunits are uncommon in human
cancers because these are required genes for cell viability. In
contrast, truncating loss of function mutations in STAG2 are likely
selected for in human cancers because STAG2 inactivation is not
an essential gene, but instead is a critical regulator of cohesin
function that when subverted promotes tumorigenesis without
perturbing the essential functions of the core cohesin ring.
Our studies reveal that STAG2 is a critical mediator at the
replication fork that governs interaction of the cohesin ring with
the replication machinery. STAG2 deficiency in primary non-
transformed human cells induces an intra-S-phase arrest due to
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stalling of replication forks. We demonstrate across a spectrum of
human cell lines that the cohesin ring physically associates with a
multitude of key replication factors including the MCM helicase
complex, replication licensing factors such as Geminin and
CDT1, and the replisome machinery including PCNA and DNA
polymerases. In the absence of STAG2, the cohesin ring is more
robustly bound to the replication licensing inhibitor Geminin, the
single-strand DNA binding protein RPA2/p34, and the MCM
helicase complex. In contrast, the interaction of the cohesin ring
with replisome components PCNA, PolD, and PolE is disrupted,
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whereas the interaction with other replisome components
including CDC45 and AND1 remains stable. These findings
indicate that the interaction of the cohesin ring with the pre-
replication complex and the active replication machinery during S
phase is a complex and dynamic process, which is perturbed by
the absence of STAG2. We speculate that the binding of cohesin
with Geminin may represent a critical mediator of an intra-S-
phase checkpoint to ensure establishment of sister chromatid
cohesion during DNA replication. The disruption of cohesin
binding with the replication factors PCNA, PolD, and PolE upon
STAG2 depletion may represent either lack of recruitment to the
active replication fork or instability and dissociation from the
stalled replication fork. Regardless of the mechanism, this results
in stalling of DNA synthesis, accumulation of single-stranded
DNA binding protein RPA2/p34 at replication sites, and even-
tually fork collapse (Fig. 9).
We find that STAG2 is required to establish acetylation of
SMC3 during DNA replication, a post-translational modification
that has been reported as being critical for efficient DNA repli-
cation39. However, we show that SMC3 acetylation is actually
dispensable for DNA replication, as concurrent STAG2 and TP53
inactivation results in a bypass of the intra-S-phase arrest despite
failure to establish SMC3 acetylation. These results show that
SMC3 acetylation is not required for DNA replication in cancer
cells with TP53 mutation, but instead suggest that SMC3 acet-
ylation is critical for controlling activation of an S-phase check-
point that ensures establishment of sister chromatid cohesion
during DNA synthesis. These results also help to explain the
frequent co-occurrence of STAG2 and TP53 mutations in human
cancers including Ewing sarcoma24,28. STAG2 mutation disrupts
stability of the replication fork leading to fork collapse and DNA
double-strand breaks, which in normal cells with intact TP53
a b
Agent Mode of action 
Effect of STAG2 
inactivation
H4 parental (STAG2 mutant)
H4 STAG2 KI (wildtype) 
Log [etoposide], nM Log [rucaparib], μM
Log [VX-970], nM Log [panobinostat], nM
Fr
ac
tio
n 
su
rv
iv
al
Fr
ac
tio
n 
su
rv
iv
al
Fr
ac
tio
n 
su
rv
iv
al
Fr
ac
tio
n 
su
rv
iv
alCyclophosphamide
Gemcitabine
Temozolomide
Cisplatin
Doxorubicin
Topotecan
Etoposide
Vincristine
Olaparib
Rucaparib
VX-970
AZD6738
Imatinib
Sorafenib
Everolimus
Panobinostat
Actinomycin D
Bortezomib
DNA alkylating
DNA alkylating
DNA alkylating
DNA crosslinking
Topoisomerase-ll lnh.
Topoisomerase-ll lnh.
Topoisomerase-ll lnh.
Microtublue lnh.
PARP lnh.
PARP lnh.
ATR  kinase lnh.
ATR  kinase lnh.
Tyrosine kinase lnh.
Tyrosine kinase lnh.
mTOR lnh.
HDAC lnh.
RNA Polymerase lnh.
Proteasome lnh.
Sensitization
Sensitization
Sensitization
Sensitization
Sensitization
Sensitization
Sensitization
No change
Sensitization
Sensitization
Sensitization
Sensitization
No change
No change
No change
No change
No change
1.2
1.0
0.8
0.6
0.4
0.2
0.0
1.2
1.0
0.8
0.6
0.4
0.2
0.0
1.2
1.0
0.8
0.6
0.4
0.2
0.0
1.2
1.0
0.8
0.6
0.4
0.2
0.0
0.1 1 10 100 1000 10,000 0.1 1 10 100
1 10 100 1000 0.1 1 10 100 1000
No change
Fig. 8 STAG2 deficient cancer cells harbor increased sensitivity to cytotoxic chemotherapeutic agents and small molecule inhibitors of DNA double-strand
break repair. a Summary of results from chemotherapeutic screen in four pairs of STAG2 isogenic human cells (H4 glioblastoma, 42MGBA glioblastoma,
TC-106 Ewing sarcoma, and RPE hTERT shTP53). All four pairs showed similar sensitivities for all agents. b Survival plots of STAG2 isogenic H4
glioblastoma cells following treatment with etoposide (topoisomerase II inhibitor), rucaparib (PARP inhibitor), VX-970 (ATR inhibitor), and panobinostat
(HDAC inhibitor). Each data point is the mean of 12 replicates from 3 independent experiments, and error bars show standard error of the mean. Source
data are provided as a Source Data file
Fig. 7 STAG2 deficiency in human cancer cells creates a synthetic lethality with DNA double-strand break repair factors and increased sensitivity to ionizing
radiation. a Quantitation of survival from shRNA synthetic lethality screen in STAG2 isogenic H4 glioblastoma cells (parental= STAG2mutant, STAG2 KI=
wildtype). Each data point is the mean of 8 replicates from 2 independent experiments, and error bars show standard error of the mean. b Representative
phase contrast images of STAG2 isogenic H4 glioblastoma cells showing synthetic lethality of STAG2 inactivation with shRNA depletion of the non-
homologous end joining factor DNA-PKcs. c Quantitation of survival from shRNA synthetic lethality screen in STAG2 isogenic RPE shTP53 cells. Each data
point is the mean of 8 replicates from 2 independent experiments, and error bars show standard error of the mean. d Representative phase contrast images
of STAG2 isogenic RPE shTP53 cells showing synthetic lethality of STAG2 knockout with shRNA depletion of the non-homologous end joining factor DNA-
PKcs, but not the base excision repair factor DNA polymerase β. e Summary of results from shRNA synthetic lethality screen in four pairs of STAG2
isogenic human cells (H4 glioblastoma, 42MGBA glioblastoma, TC-106 Ewing sarcoma, and RPE hTERT shTP53). HR, homologous recombination. NHEJ,
non-homologous end joining. BER, base excision repair. NER, nucleotide excision repair. f Survival plots of STAG2 isogenic H4 glioblastoma cells (parental
= STAG2 mutant, STAG2 KI=wildtype) following gamma irradiation or ultraviolet irradiation. Each data point is the mean of 12 replicates from 3
independent experiments, and error bars show standard error of the mean. Source data are provided as a Source Data file
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leads to checkpoint activation and senescence. However, in cells
with concurrent TP53 inactivation, the fork collapse and DNA
double-strand breaks induced by STAG2 deficiency likely pro-
motes tumorigenesis by facilitating oncogenic structural variants
such as gene amplifications, deletions, and rearrangements.
Indeed, an increased quantity of chromosomal structural variants
is found in STAG2 mutant versus STAG2 wildtype Ewing
sarcomas28,42.
We find that a consequence of the replication fork instability
caused by STAG2 inactivation in human cells is a critical
dependence on DNA double-strand break repair factors. STAG2
deficient cells show profound sensitivity to depletion of genes
involved in homologous recombination and non-homologous
end-joining, but not excision repair pathways. Additionally, we
find that STAG2 mutant cancer cells have increased sensitivity to
ionizing radiation and cytotoxic chemotherapeutic agents (e.g.,
cyclophosphamide and etoposide) that function by inducing
DNA double-strand breaks. Furthermore, PARP1 or ATR inhi-
bition constitutes a STAG2 synthetic lethal interaction that can be
elicited with clinical inhibitors such as olaparib or AZD6738,
which are currently FDA-approved and in phase II clinical trials,
respectively. These effects were robust across isogenic cell models
of different tumor types, both glioblastoma and Ewing sarcoma,
as well as an immortalized epithelial cell line. These findings have
significant treatment implications for STAG2 mutant cancers,
suggesting a greater benefit from radiation therapy and che-
motherapeutic agents that induce DNA double-strand breaks.
In summary, STAG2 mutations are a frequent characteristic of
a few of the most common human cancers including
glioblastoma, urothelial carcinoma, and Ewing sarcoma. Here we
show that cohesin has critical functions at the DNA replication
fork regulated by STAG2, and that the replication fork instability
caused by STAG2 inactivation creates a targetable synthetic
lethality in cohesin-mutant cancers. Together with other recent
studies showing enhanced PARP inhibitor sensitivity in cohesin-
deficient cells43,44, these studies lay the foundation for clinical
trials of targeted agents in STAG2 mutant cancers.
Methods
Human cell lines and culture conditions. The list of human cell lines used in this
study and their source is provided in Supplementary Table 1. All cell lines were
cultured in DMEM supplemented with 10% fetal bovine serum and 1% penicillin/
streptomycin. Cell cultures were maintained at 37 °C in a humidified incubator
with 5% carbon dioxide. H4 and 42MGBA human glioblastoma cell lines harboring
endogenous truncating mutations in the STAG2 gene and their isogenic STAG2
knock-in counterparts in which the mutant alleles have been corrected to wildtype
status by homologous recombination were previously described26.
Lentiviral shRNA constructs and CRISPR guide RNA. All lentiviral shRNA
expression plasmids were obtained from Dharmacon that had been generated by
The RNAi Consortium (TRC) in the pLKO.1-Puro lentiviral expression vector or
in the pGIPZ lentiviral expression vector. Sequence of the short hairpin RNAs are
listed in Supplementary Table 2. Five independent shRNA clones were used for
STAG2, five independent shRNA clones were tested for each of the cohesin
components, and five independent shRNA clones were tested for each of the ten
DNA repair factor genes included in the synthetic lethality screen. shRNA clones
were received from Dharmacon as stabs in Luria agar, which were then cultured on
Luria agar plates containing 100 μg/mL ampicillin. Single colonies were isolated for
plasmid preparation (Qiagen). Sanger sequencing confirmation was performed
over the hairpin sequence for all lentiviral shRNA expression constructs. A guide
RNA against STAG2 that had been cloned into the BamHI restriction site of pCas-
Guide-EF1a-GFP construct was obtained from OriGene. Sequence of the STAG2
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guide RNA and sequencing primers are listed in Supplementary Table 2. Sanger
sequencing confirmation was performed over the guide RNA sequence after
plasmid preparation.
CRISPR induced mutagenesis of the STAG2 gene in human cell lines. hTERT-
immortalized RPE cells, hTERT-immortalized RPE shTP53 cells, hTERT-immortalized
BJ cells, EW2 Ewing sarcoma cells, TC-71 Ewing sarcoma cells, and TC-106 Ewing
sarcoma cells were used for CRISPR induced mutagenesis of the STAG2 gene. Expo-
nentially proliferating cells were transfected with the pCas-STAG2 gRNA-EF1a-GFP
construct using FuGENE 6 according to the manufacturer’s protocol. At 48 h post-
transfection, cells were collected by trypsinization and GFP-positive cells were sorted
using a Sony SH800 Cell Sorter. Sorted cells were diluted, and single GFP-positive cells
were placed into wells of a 96-well plate for isolation of single cell clones. Single cell
clones were expanded, and a subset of the cells were used for genomic DNA isolation
for assessment of STAG2 gene status. Genomic DNA was isolated via proteinase K
digestion, phenol-chloroform extraction, and subsequent ethanol precipitation. Primers
were used to amplify a portion of the STAG2 gene that included the sequence targeted
by the guide RNA using the MyFi DNA Polymerase Kit, and Sanger sequencing using
BigDye terminators was performed to visualize Cas9 cleavage. CRISPR efficiency was
assessed as the number of clones with evidence of Cas9 cleavage divided by the total
number of clones screened. Cell lysate was prepared from individual clones found to
have Cas9 induced frameshift mutations predicted to cause premature truncation of the
encoded STAG2 protein, and immunoblots were performed using a monoclonal
antibody raised against an epitope at the C-terminus of the STAG2 protein (clone J-12,
Santa Cruz sc-81852) as described in detail below.
Lentivirus production and infection for shRNA transduction. Empty pLKO.1
vector or gene specific pLKO.1-shRNA vectors were co-transfected into 293T cells
with pVSV-G and pCMV 8.2-deltaR helper plasmids using FuGENE 6 according to
the manufacturer’s protocol. Empty pGIPZ vector or pGIPZ-STAG2 shRNA vec-
tors were co-transfected into 293T cells with the Dharmacon Trans-Lentiviral
Packaging Plasmid System using FuGENE 6 according to the manufacturer’s
protocol. Virus-containing conditioned medium was harvested 48 h after trans-
fection, filtered, and used to infect recipient cells in the presence of 5 µg/mL
polybrene.
Flow cytometric analysis of cell cycle. RPE, BJ, and SVG p12 cells either syn-
chronized with drugs or treated with lentiviral shRNA conditioned media were
collected by trypsinization and washed with PBS. Cells were re-suspended and
fixed with 70% ethanol at 4 °C for 1 h. Fixed cells were washed in PBS and stained
with propidium iodide (50 μg/mL) containing RNAse (100 μg/mL) for 30 min in
the dark. Fifteen thousand stained cells per experimental condition were assessed
using a BD LSRFortessa cell analyzer and BD FACSDiva software (BD Biosciences).
The following drugs were used: DMSO vehicle, aphidicolin (2 μg/mL, for 48 h),
palbociclib (1 μM, for 48 h), colcemid (0.5 μg/mL, for 16 h). Flow cytometric
analysis was performed following treatment with lentiviral shRNAs at multiple
time points as indicated.
Immunoprecipitation and Western blotting. Total lysate was harvested from
experimental cells in RIPA buffer (Pierce) supplemented with protease inhibitor
cocktail (Pierce) at 4 °C. Lysate was centrifuged at 16,000 × g to remove insoluble
material. Protein concentration of the total soluble lysates were measured using
BCA protein assay kit (Pierce). For immunoprecipitation, cells were harvested in IP
Lysis buffer (Pierce) supplemented with protease and phosphatase inhibitor
cocktail (Pierce) at 4 °C. For evaluation of SMC3 acetylation, the IP lysis buffer was
supplemented with 5 mM sodium butyrate (a deacetylase inhibitor). Protein-A
sepharose beads (Abcam) were blocked in 0.1% BSA for 1 h and then incubated
with the indicated primary antibodies for 1 hour at 4 °C with gentle mixing.
Antibody-conjugated beads were then centrifuged and washed with cell lysis buffer
before adding to the cell lysate. Immunoprecipitation was performed overnight
with gentle mixing at 4 °C, followed by centrifugation and washing of the beads
with lysis buffer. A subset of the immunoprecipitation reactions were treated with
DNase I (New England Biolabs, 10 units used per immunoprecipitation reaction)
or micrococcal nuclease (Thermo Scientific, 500 units used per immunoprecipi-
tation reaction) for 2 h at room temperature prior to washing of the beads with
lysis buffer.
Total cell lysates and immunoprecipitates were denatured with Bolt Sample
Reducing Agent in NuPAGE LDS Sample Buffer at 94 oC for 10 min. Poly-
acrylamide gel electrophoresis was performed using Bolt 4–12% Bis-Tris Plus
gradient gels. Resolved proteins were transferred onto nitrocellulose membranes
using iBlot2 NC Transfer Stacks and iBlot2 Gel Transfer Device according to the
manufacturer’s protocol (Life Technologies). Primary and HRP-conjugated
secondary antibodies were diluted with iBind Flex Solution. The iBind Flex
chromatography system (Life Technologies) was used for all Western blots.
Chemiluminescence was performed using SuperSignal West Pico PLUS
Chemiluminescent Substrate for 2 min. Chemiluminescence signal was recorded on
Xposure film (Thermo Scientific) followed by development in X-ray film processer
(JP-33, JPI Healthcare). The list of antibodies used for immunoprecipitation and
Western blotting and their source is provided in Supplementary Table 3.
Immunofluorescence and microscopy. For 53BP1 immunofluorescence, cells
were seeded on glass coverslips and irradiated or transduced with lentiviral
shRNAs after 24 h. Cells were fixed at the indicated time points following gamma-
radiation and at 48 h after lentiviral shRNA transduction. Cells were fixed with 10%
neutral-buffered formalin, permeabilized with 0.2% Triton X-100, pre-incubated
with 10% BSA in PBS, and then incubated with 53BP1 primary antibody overnight
at 4 °C. Cover slips were washed, incubated with fluorescent-conjugated secondary
antibodies (Molecular Probes) for 2 h at room temperature, followed by counter-
staining and mounting on glass slides with Vectashield Mounting Medium con-
taining DAPI (Vector Labs). The list of antibodies used for immunofluorescence
and their source is provided in Supplementary Table 3.
Nuclear localization of the p34 subunit of replication protein A (RPAp34) was
assessed using a GFP-tagged human RPA2 cDNA construct that has been
previously described32,45. The GFP-RPAp34 construct was transfected into RPE
cells using FuGENE 6 according to the manufacturer’s protocol. Treatment with 1
μg/mL aphidicolin or 0.5 μM etoposide was initiated at 48 h after transfection.
Alternatively, transduction with two independent STAG2 lentiviral shRNAs was
performed at 24 h after transfection. Cells were pulsed with 5-bromo-2′-
deoxyuridine (BrdU) for 30 min prior to fixation with 10% neutral-buffered
formalin. BrdU pulse and fixation was at 16 h after aphidicolin or etoposide
treatment and 48 h after lentiviral shRNA transduction. Cells were permeabilized
with 0.2% Triton X-100, treated with 20 U/mL DNase I in PBS, and then incubated
with anti-BrdU primary antibody overnight at 4 oC. Cover slips were washed,
incubated with fluorescent-conjugated secondary antibodies (Molecular Probes) for
2 h at room temperature, followed by counterstaining and mounting on glass slides
with Vectashield Mounting Medium containing DAPI (Vector Labs).
Beta-galactosidase activity was assessed on RPE, BJ, and SVG p12 cells at
14 days following lentiviral transduction with empty pLKO.1 or two independent
STAG2 shRNAs. Cells were washed with PBS, fixed in 1× Fixative Solution, and
incubated with the freshly prepared β-Galactosidase Staining Solution overnight at
37 °C according to manufacturer’s protocol (Senescence b-Galactosidase Staining
Kit, Cell Signaling).
Fluorescent imaging was performed on a Leica TCS SP8 laser scanning confocal
microscope (DMi8 platform) using Leica Application Suite X software and Leica
PCO Edge 5.5 sCMOS camera. Imaging was performed using either 100×/1.44 oil-
immersion HC Plan Apo objective lens or 60×/1.40 oil-immersion HC Plan Apo
CS2 objective lens. Excitation used Leica Express UI white light lasers, and
multidimensional image acquisition was performed using a combination of PMT
and HyD detectors for multiple fluorescent dyes. Sequential scans were performed
between frames to minimize fluorescence bleed through among multiple
fluorophores. A pinhole value of 1.0 was used for 53BP1 imaging, while a pinhole
of 3.0 was used for single fiber DNA replication fork imaging. Images were
acquired in 1024 × 1024 pixel format, and 3–8 line averages or frame averages were
recorded at moderate speed (100–200). For quantification of 53BP1 foci,
approximately 2,000 cells were evaluated from two independent experiments for
each condition. For quantification of cells with GFP-RPAp34 foci, approximately
600 cells were evaluated from three independent experiments for each condition.
Phase contrast imaging was performed on an Olympus CKX53 inverted
microscope equipped with an Olympus DP27 CCD camera using Olympus LCAch
N objectives and Olympus cellSens imaging software.
Single fiber DNA replication fork progression analysis. Analysis of single fiber
DNA replication fork progression was performed in hTERT-immortalized human
RPE cells. See experimental schematic in Fig. 2a. Lentiviral transduction with
empty pLKO.1 or two independent STAG2 shRNAs was performed on exponen-
tially growing cells. At 48 h following infection, culture media was supplemented
with the DNA nucleotide analog 5-iodo-2′-deoxyuridine (IdU) to a final con-
centration of 25 µM. Following pulse with IdU at 37 °C for 30 min, cells were
washed with media. Cells were then incubated in cell culture media supplemented
with the DNA nucleotide analog 5-chloro-2′-deoxyuridine (CldU) to a final con-
centration of 250 µM at 37 °C for another 30 min. Following this second pulse with
CldU, cells were trypsinized and washed with chilled PBS. Cells were then counted
and re-suspended at a concentration of 5 × 105 cells/mL in chilled PBS. Two
microliter of the cell suspension was spotted at the end of glass slides. Cells were
allowed to air dry for approximately 5 min to reduce the volume significantly, but
not to completely dry. Subsequently, 7 µL of the cell lysis solution (200 mM Tris-
HCl, pH 7.5, 50 mM EDTA, and 0.5% SDS) was applied on top of the cell sus-
pension, mixed by gently stirring with a pipette tip, and allowed to lyse for 2 min.
Slides were then tilted to approximately 15° to allow the DNA fibers to slowly flow
across the slide and subsequently allowed to dry. Slides were then fixed with a
solution of methanol and acetic acid (3:1) for 10 min at room temperature. Sub-
sequently, slides were washed in distilled water and immersed in 2.5 M hydro-
chloric acid for 90 min. After DNA denaturation, slides were washed three times
with PBS for 5 min each. After removal of excess PBS, the area of the slide con-
taining DNA fibers was circled with an ImmEdge pen (Vector Labs, H-4000). In a
humidified chamber at room temperature, slides were covered with blocking
solution (5% BSA in PBS) for 15 min followed by the primary antibody solution
(mouse anti-BrdU clone B44 at 1:25 dilution and rat anti-BrdU clone BU1/75
(ICR1) at 1:400 dilution in blocking solution) for 3 h. Subsequently, slides were
washed three times with PBS for 5 min each, followed by incubation with
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secondary antibody solution (sheep anti-mouse Cy3-conjugated at 1:500 dilution
and goat anti-rat Alexa Fluor 488-conjugated at 1:400 dilution in blocking solu-
tion) for 90 min at room temperature. Finally, slides were washed three times with
PBS, and allowed to air dry before mounting with Vectashield Mounting Medium.
Slides were sealed with coverslip sealant. In order to validate this single fiber DNA
replication fork assay, this analysis was also performed on un-infected, exponen-
tially growing RPE cells after introduction of the DNA polymerase inhibitor
aphidicolin at 10 μg/mL at various timepoints before and during the IdU and CldU
nucleotide pulses. See experimental schematic in Supplementary Fig. 2a.
Imaging of the single fiber DNA replication forks was performed using a Leica
TCS SP8 laser scanning confocal microscope and Leica Application Suite X software
as described in the microscopy section above. Imaging and assessment was performed
in regions where fibers were well separated and not entangled. Greater than 200
individual replication forks were evaluated from more than 20 fields from two
independent experiments per condition. Evaluation and quantification was performed
in a blinded fashion to prevent bias. A summary of the replication fork categorization
is shown in Fig. S2C and is described here. Fibers with equal IdU and CldU labeling
were categorized as unidirectional elongating fork (normal fork progression). Fibers
with CldU labeling at both ends of IdU labeling were categorized as bi-directional
replication (normal fork progression). Fibers with ldU labeling at both ends of CIdU
labeling were categorized as completion of replication (normal fork progression).
Fibers with CldU labeling only were categorized as new origin of replication during
second pulse (indeterminate fork progression, excluded from quantitation shown in
Fig. 2c). In contrast, abnormal fork progression was scored for fibers with absence of
CldU labeling (stalled fork during first pulse), fibers with unequal IdU and CldU
labeling (either stalled fork during second pulse or stalled fork during first pulse with
re-initiation), or fibers with both minimal IdU and CldU labeling (stalled fork
throughout both pulses). Quantitation of normal fork progression versus abnormal
fork progression is shown in Fig. 2c following lentiviral transduction with empty
pLKO.1 or two independent STAG2 shRNAs, while detailed quantitation of the
individual categories of replication fork progression are shown in Supplementary
Fig. 2d.
Cell cycle-dependent 53BP1 foci analysis. U87MG human glioblastoma cells
were synchronized in G1 phase of the cell cycle by culturing in the presence of 1
µM palbociclib for 48 h. Following synchronization, lentiviral transduction with
empty pLKO.1 or STAG2 shRNA was performed, and selection with 2 μg/mL
puromycin was initiated at 24 h after infection. Following completion of puromycin
selection, cells were released from palbociclib arrest and fixed for immuno-
fluorescence at the indicated time points. See experimental schematic in Supple-
mentary Fig. 4a. Depletion of STAG2 protein was confirmed by immunoblotting.
Radiation, drug treatment, and shRNA synthetic lethality screen. The
CellTiter-Glo assay (Promega) was used to assess cell survival following radiation,
drug treatment, or lentiviral shRNA transduction of four pairs of STAG2 isogenic
human cell lines. 500 exponentially growing cells were seeded per well in clear-
bottom white polystyrene 96-well microplates (Corning 3903). At 24 h after
seeding, cells were irradiated, treated with various drugs, or lentiviral shRNAs as
indicated. At 4 days following treatment, an equal volume of CellTiter-Glo One
Solution reagent was added to each of the wells, followed by shaking for five min at
120 rpm at room temperature. Luminescence was measured using the SpectraMax
M5 spectrophotometer (Molecular Devices). For gamma irradiation, cultured cells
were exposed to radioactive cesium isotope (Cs-137) at the indicated dosage.
Ultraviolet irradiation was delivered using the UV Stratalinker-2400 (Stratagene) at
the indicated dosage. All drugs used for the cell survival assays were obtained from
Selleck Chemicals or Tocris Bioscience. All drugs were dissolved in DMSO, except
for cisplatin that was dissolved in N,N-dimethylformamide. Drugs were used at the
indicated concentrations. Five independent lentiviral shRNAs for each of the 10
DNA repair genes included in the shRNA synthetic lethality screen were first tested
on the U87MG human glioblastoma cell line to determine the two shRNAs that
produced the most efficient depletion as assessed by Western blot. Two indepen-
dent shRNAs were then used to conduct the synthetic lethality screen for each of
the 10 DNA repair genes in the four STAG2 isogenic human cell lines. For the
gamma and ultraviolet irradiation experiments, 12 replicates from 3 independent
experiments were performed for each experimental condition. For the drug screen,
12 replicates from 3 independent experiments were performed for each experi-
mental condition. For the shRNA synthetic lethality screen, 8 replicates from 2
independent experiments were performed for each experimental condition. Percent
survival was assessed as the mean luminescence of the experimental condition
relative to the mean luminescence of the control cells (either no radiation, DMSO
vehicle, or empty pLKO.1).
Clonogenic survival assay. Four pairs of isogenic STAG2 human cell lines (H4,
42MGBA, TC-106, and RPE-shTP53) were used. Five hundred cells were seeded
per well in 6-well plates. After 24 h, DMSO vehicle or cyclophosphamide at the
indicated dosages was added to the culture media. Cultures were maintained for
two weeks to allow colony formation, with repletion of media supplemented with
fresh DMSO or cyclophosphamide every two days. Plates were stained with 0.5%
crystal violet in 25% methanol solution. Colonies were imaged and counted using
the GelCount instrument (Oxford Optronix). Three replicates were performed for
each experimental condition.
Quantification and statistical analysis. Statistical analysis was performed using
GraphPad Prism or Microsoft Excel. All error bars shown represent standard error
of the mean. All statistical details of experiments are included in the Figure legends
or specific Methods section.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying Figs. 1–8 and Supplementary Figures 1-8 are provided as a
Source Data file. A reporting summary for this Article is available as a Supplementary
Information file. All data is available from the authors upon reasonable request.
Received: 12 September 2018 Accepted: 25 March 2019
References
1. Nasmyth, K., Peters, J. M. & Uhlmann, F. Splitting the chromosome: cutting
the ties that bind sister chromatids. Science 288, 1379–1385 (2000).
2. Canudas, S. & Smith, S. Differential regulation of telomere and centromere
cohesion by the Scc3 homologues SA1 and SA2, respectively, in human cells. J.
Cell. Biol. 187, 165–173 (2009).
3. Remeseiro, S. et al. Cohesin-SA1 deficiency drives aneuploidy and
tumourigenesis in mice due to impaired replication of telomeres. EMBO J. 31,
2076–2089 (2012).
4. Rao, S. S. P. et al. Cohesin loss eliminates all loop domains. Cell 171, 305–320
(2017).
5. Vian L., et al. The energetics and physiological impact of cohesin extrusion.
Cell 173, 1165–1178 (2018).
6. Haarhuis, J. H. I. et al. The cohesin release factor WAPL restricts chromatin
loop extension. Cell 169, 693–707 (2017).
7. Parelho, V. et al. Cohesins functionally associate with CTCF on mammalian
chromosome arms. Cell 132, 422–433 (2008).
8. Busslinger, G. A. et al. Cohesin is positioned in mammalian genomes by
transcription, CTCF and Wapl. Nature 544, 503–507 (2017).
9. Guillou, E. et al. Cohesin organizes chromatin loops at DNA replication
factories. Genes Dev. 24, 2812–2822 (2010).
10. Haering, C. H., Farcas, A. M., Arumugam, P., Metson, J. & Nasmyth, K. The
cohesin ring concatenates sister DNA molecules. Nature 454, 297–301 (2008).
11. Lengronne, A. et al. Establishment of sister chromatid cohesion at the S.
cerevisiae replication fork. Mol. Cell 23, 787–799 (2006).
12. Takahashi, T. S., Yiu, P., Chou, M. F., Gygi, S. & Walter, J. C. Recruitment of
Xenopus Scc2 and cohesin to chromatin requires the pre-replication complex.
Nat. Cell. Biol. 6, 991–996 (2004).
13. Zheng, G., Kanchwala, M., Xing, C. & Yu, H. MCM2-7-dependent cohesin
loading during S phase promotes sister-chromatid cohesion. Elife 7, e33920
(2018).
14. Frattini, C. et al. Cohesin ubiquitylation and mobilization facilitate stalled
replication fork dynamics. Mol. Cell 68, 758–772 (2017).
15. Tittel-Elmer M., et al. Cohesin association to replication sites depends on
rad50 and promotes fork restart. Mol. Cell 48, 98–108 (2012).
16. Carvajal-Maldonado D., et al. Perturbing cohesin dynamics drives MRE11
nuclease-dependent replication fork slowing. Nucleic Acids Res. (2018) [Epub
ahead of print Jun 18].
17. Deardorff, M. A. et al. HDAC8 mutations in Cornelia de Lange syndrome
affect the cohesin acetylation cycle. Nature 489, 313–317 (2012).
18. Deardorff, M. A. et al. RAD21 mutations cause a human cohesinopathy. Am.
J. Hum. Genet. 90, 1014–1027 (2012).
19. Mullegama, S. V. et al. De novo loss-of-function variants in STAG2 are
associated with developmental delay, microcephaly, and congenital anomalies.
Am. J. Med. Genet. A 173, 1319–1327 (2017).
20. Tonkin, E. T., Wang, T. J., Lisgo, S., Bamshad, M. J. & Strachan, T. NIPBL,
encoding a homolog of fungal Scc2-type sister chromatid cohesion proteins
and fly Nipped-B, is mutated in Cornelia de Lange syndrome. Nat. Genet. 36,
636–641 (2004).
21. Kaur, M. et al. Precocious sister chromatid separation (PSCS) in Cornelia de
Lange syndrome. Am. J. Med. Genet. A 138, 27–31 (2005).
22. Yuan, B. et al. Global transcriptional disturbances underlie Cornelia de Lange
syndrome and related phenotypes. J. Clin. Invest. 125, 636–651 (2015).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09659-z ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1686 | https://doi.org/10.1038/s41467-019-09659-z | www.nature.com/naturecommunications 15
23. Liu, J. et al. Transcriptional dysregulation in NIPBL and cohesin mutant
human cells. PLoS Biol. 7, e1000119 (2009).
24. Brohl, A. S. et al. The genomic landscape of the Ewing Sarcoma family of
tumors reveals recurrent STAG2 mutation. PLoS Genet. 10, e1004475 (2014).
25. Solomon, D. A. et al. Frequent truncating mutations of STAG2 in bladder
cancer. Nat. Genet. 45, 1428–1430 (2013).
26. Solomon, D. A. et al. Mutational inactivation of STAG2 causes aneuploidy in
human cancer. Science 333, 1039–1043 (2011).
27. Balbas-Martinez, C. et al. Recurrent inactivation of STAG2 in bladder cancer
is not associated with aneuploidy. Nat. Genet. 45, 1464–1469 (2013).
28. Tirode, F. et al. Genomic landscape of Ewing sarcoma defines an aggressive
subtype with co-association of STAG2 and TP53 mutations. Cancer Discov. 4,
1342–1353 (2014).
29. Kon, A. et al. Recurrent mutations in multiple components of the cohesin
complex in myeloid neoplasms. Nat. Genet. 45, 1232–1237 (2013).
30. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across
21 tumour types. Nature 505, 495–501 (2014).
31. Shen, C. H. et al. Loss of cohesin complex components STAG2 or STAG3
confers resistance to BRAF inhibition in melanoma. Nat. Med. 22, 1056–1061
(2016).
32. Solomon, D. A., Cardoso, M. C. & Knudsen, E. S. Dynamic targeting of the
replication machinery to sites of DNA damage. J. Cell. Biol. 166, 455–463
(2004).
33. Wohlschlegel, J. A. et al. Inhibition of eukaryotic DNA replication by geminin
binding to Cdt1. Science 290, 2309–2312 (2000).
34. Mihaylov, I. S. et al. Control of DNA replication and chromosome ploidy by
geminin and cyclin A. Mol. Cell Biol. 22, 1868–1880 (2002).
35. Beckouet, F. et al. An Smc3 acetylation cycle is essential for establishment of
sister chromatid cohesion. Mol. Cell 39, 689–699 (2010).
36. Chan, K. L. et al. Cohesin’s DNA exit gate is distinct from its entrance gate
and is regulated by acetylation. Cell 150, 961–974 (2012).
37. Ladurner, R. et al. Cohesin’s ATPase activity couples cohesin loading onto
DNA with Smc3 acetylation. Curr. Biol. 24, 2228–2237 (2014).
38. Rolef Ben-Shahar, T. et al. Eco1-dependent cohesin acetylation during
establishment of sister chromatid cohesion. Science 321, 563–566 (2008).
39. Terret, M. E., Sherwood, R., Rahman, S., Qin, J. & Jallepalli, P. V. Cohesin
acetylation speeds the replication fork. Nature 462, 231–234 (2009).
40. Benedetti, L., Cereda, M., Monteverde, L., Desai, N. & Ciccarelli, F. D.
Synthetic lethal interaction between the tumour suppressor STAG2 and its
paralog STAG1. Oncotarget 8, 37619–37632 (2017).
41. van der Lelij P., et al. Synthetic lethality between the cohesin subunits STAG1
and STAG2 in diverse cancer contexts. Elife 6, e26980 (2017).
42. Crompton, B. D. et al. The genomic landscape of pediatric Ewing sarcoma.
Cancer Discov. 4, 1326–1341 (2014).
43. Liu Y., et al. Somatic mutation of the cohesin complex subunit confers
therapeutic vulnerabilities in cancer. J. Clin. Invest. 128, 2951–2965 (2018).
44. McLellan, J. L. et al. Synthetic lethality of cohesins with PARPs and replication
fork mediators. PLoS Genet. 8, e1002574 (2012).
45. Sporbert, A., Gahl, A., Ankerhold, R., Leonhardt, H. & Cardoso, M. C. DNA
polymerase clamp shows little turnover at established replication sites but
sequential de novo assembly at adjacent origin clusters. Mol. Cell 10,
1355–1365 (2002).
Acknowledgements
We thank Asmin Tulpule, Bjoern Schwer, Chris Lord, and members of the Ashworth
laboratory for helpful discussions. We thank Svetlana Kraus for flow cytometry assis-
tance, William Walantus for confocal imaging assistance, Enrico Joaquin for gamma-
irradiation assistance, and Sarah Pyle for assistance with graphic design. This study was
supported by the NIH Director’s Early Independence Award (DP5 OD021403) and the
UCSF Physician-Scientist Scholar Program to D.A.S. Flow cytometry analysis was per-
formed at the UCSF Parnassus Flow Cytometry Core (NIH P30 DK063720). Confocal
imaging was performed at the Imaging Core for the UCSF Eli and Edythe Broad Center
of Regeneration Medicine and Stem Cell Research.
Author contributions
Experimental design: G.M., A.A., and D.A.S.; experiment execution: G.M. and B.G.; data
analysis and Figs: G.M., M.S., and D.A.S.; manuscript preparation: G.M. and D.A.S. with
comments from all authors.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-09659-z.
Competing interests: A.A. declares that he is a consultant for: AtlasMDX, Third Rock
Ventures, Pfizer, Sun Pharma, Bluestar, TopoRx and ProLynx; member of the Scientific
Advisory Board of Genentech, GLAdiator and Driver; receives grant support from Sun
Pharma and AstraZeneca; is co-founder of Tango Therapeutics; and is a shareholder of
Syncona. The remaining authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Journal Peer Review Information: Nature Communications thanks Lena Ström, and
other anonymous reviewer(s) for their contribution to the peer review of this work. Peer
reviewer reports are available.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09659-z
16 NATURE COMMUNICATIONS |         (2019) 10:1686 | https://doi.org/10.1038/s41467-019-09659-z | www.nature.com/naturecommunications
